Data Snapshot - Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)

The HSE Medicines Management Programme provide insights into prescribing trends and utilisation for medicines and non-drug products available through the HSE. This Data Snapshot provides an update on utilisation of medicines reimbursed for the treatment of transthyretin amyloidosis with cardiomyopathy (ATTR-CM) subject to a managed access protocol.